Christensenellaceae bacteria including christensenella minuta and uses thereof
Christensenella minuta strain DSM32891 addresses the limitations of current treatments for mood disorders by modulating hormonal stress responses and alleviating depressive behavior, offering a promising therapeutic approach for mood and anxiety disorders.
Patent Information
- Application Number
- JP2024143324
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-11-28
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for mood disorders such as depression are only partially effective, with many patients experiencing subclinical symptoms or no improvement, and there is a lack of understanding of the molecular mechanisms underlying these conditions, which are often associated with dysbiosis of the intestinal microbiota.
The use of Christensenella minuta strain DSM32891, its cellular components, metabolites, and secreted molecules, either alone or in compositions, to modulate hormonal stress responses and alleviate depressive behavior in animal models of social stress.
Demonstrates attenuation of depressive behavior and modulation of hormonal stress responses, suggesting potential therapeutic benefits for mood disorders, stress disorders, and anxiety disorders.
Smart Images

Figure 2024164175000002 
Figure 2024164175000003 
Figure 2024164175000004
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of Spanish Patent Application No. P2018 / 31153, filed November 28, 2018, which is incorporated herein by reference in its entirety.
[0002] Disclosure of sequences This application includes as part of its disclosure a biological sequence listing contained in an accompanying text file, which is incorporated herein by reference in its entirety.
[0003] The present disclosure relates to Christensenellaceae bacteria, including Christensenella minuta strain DSM32891, and their use for the prevention or treatment of mood or affective disorders, such as depression, stress disorders, and anxiety disorders. The present disclosure is in the field of therapeutic activity of pharmaceutical compositions or formulations, and also in the field of nutrition. [Background technology]
[0004] Mood disorders, especially depression, are one of the leading causes of disability worldwide. The total cost of mental disorders is estimated at 798 billion euros, of which mood disorders represent approximately 118 billion euros in direct and indirect annual costs [1]. These include major depression, typical or melancholic and atypical depression, perinatal depression, bipolar disorder, psychogenic depression, dysthymia, depressive personality disorder, seasonal affective disorder, mood disorders induced by substance abuse or by the use of drugs such as drugs of abuse, etc. Furthermore, the effectiveness of current treatments is somewhat limited. It is estimated that only about 50% of antidepressant treatments are effective, many patients retain subclinical symptoms, and others do not show improvement.
[0005] Depression is a complex medical condition characterized by the presence of heterogeneous symptoms, suggesting the existence of different forms of depression or phenotypes (e.g., typical depression, characterized by greater hyperactivity of the hypothalamic-pituitary-adrenal axis [HPA], and atypical depression, characterized by greater metabolic dysregulation and increased appetite / weight) [2, 3]. However, little is known about the molecular mechanisms underlying these medical conditions. Depression also shows high comorbidity with psychiatric disorders (e.g., anxiety) and physical disorders (e.g., cardiometabolic disorders such as metabolic syndrome, diabetes, and cerebrovascular disease), which negatively affect the course of the disease, reduce treatment response, and increase the risk of suffering from the disease.
[0006] Epidemiological studies in humans have revealed associations between alterations in the composition of the gut microbiota (dysbiosis) and psychiatric disorders such as mood or affective disorders, especially depression [4–9]. These associations between dysbiosis and depression are thought to be largely determined by psychosocial environmental factors (childhood trauma, work-related stress, lack of sleep) and lifestyle (unhealthy diet, sedentary lifestyle, medications), as well as other individual characteristics such as the genome, age, and sex of the parties, and the presence of comorbidities [2, 10]. In animal models, a stress-induced increase in HPA axis reactivity, a well-established risk factor for depression, leads to dysbiosis, and a dysbiotic microbiota, in turn, contributes to behavioral and mood disorders
[11] . Animal studies also show that a particular composition of the gut microbiota influences the response to stress, exacerbating or ameliorating its neurochemical or behavioral consequences, through mechanisms that modulate the dialogue of the immune, endocrine, or nervous systems [8, 12, 13].
[0007] The use of traditional probiotics (lactobacillus and bifidobacteria) for the treatment of depression has been shown to have different effects depending on the strain used. Bifidobacteria have perhaps been the most commonly used to evaluate their effectiveness in combating anxiety and depression, but the results obtained are not always conclusive or of sufficient magnitude [14, 15].
[0008] Besides bifidobacteria, other bacterial species may be of interest for these applications, but observational studies establishing an association between different bacterial groups and depression and showing an increase or decrease in subjects suffering from said depression are inconclusive. Thus, for example, Yu et al. (2017)
[16] observed a low proportion of the bacterial groups Marvinbryantia, Corynebacterium, Psychrobacter, Christensenella, Lactobacillus, Peptostreptococcaceae incertae sedis, Anaerovorax, Clostridiales incertae sedis, and Coprococcus in a mouse model of induced depression. However, Mironova et al. (2017)
[17] published results showing that the microbiota of patients with Parkinson's disease and moderate depression had a higher abundance of Christensenella minuta, Clostridium disporicum, and Oscillibacter valericigenes compared to patients with Parkinson's disease and minor depression or no depression.
[0009] There is therefore an ongoing search for more effective prevention and treatment strategies that could improve the management of mood disorders and thereby reduce their economic and social impact. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The present invention relates to Christensenella minuta (C. mintua) strain DSM32891 (C. minuta DSM32891), its cellular components, metabolic products and secreted molecules, as well as compositions comprising said products and their use for the prevention and / or treatment of mood disorders (such as depression), stress disorders and anxiety disorders.
[0011] The present inventors have discovered that C. minuta strain DSM32891 has the ability to attenuate depressive behavior in animals exposed to acute social stress, an effect demonstrated by oral administration of the bacteria (C. minuta strain DSM32891) to an animal model of social stress that induces depressive symptoms (see Example 2).
[0012] Furthermore, the inventors show that administration of C. minuta strain DSM32891 modulates the hormonal stress response in animals exposed to 10 days of social stress (Example 3), indicating that diseases and conditions involving hormonal stress responses may be treatable by administration of this strain.
[0013] Thus, in one aspect, the present invention relates to Christensenella minuta strain DSM 32891, hereinafter "the strain according to the invention", "C. minuta strain DSM 32891" or "strain DSM 32891".
[0014] C. minuta strain DSM32891 was isolated from feces of a healthy human. The strain was deposited by the applicant on August 7, 2018 at the Leibniz Institute DSMZ as an international depository institution under the Budapest Treaty (German Collection of Microorganisms and Cell Cultures, Inhoffenstraβe 7B, 38124 Braunschweig, Germany). The assigned deposit number was DSM32891.
[0015] The scientific classification of the strain according to the invention is: Domain: Bacteria, Phylum: Firmicutes, Class: Clostridia, Order: Clostridiales, Family: Christensenellaceae, Species: C. minuta.
[0016] Another aspect of the present invention relates to strains derived from C.minuta strain DSM32891, which maintain or improve the capabilities described throughout the present invention. The derived microorganisms can be produced naturally or by mutagenesis methods known in the prior art, such as but not limited to growing the original microorganism in the presence of mutagenic or stress-producing agents, or intentionally by genetic engineering aimed at modifying specific genes. According to a preferred embodiment, the strains derived from C.minuta strain DSM32891 are genetically modified mutants. The terms mutant strain or derived strain can be used interchangeably.
[0017] Another aspect of the invention relates to a bacterium comprising a 16S rRNA sequence having a particular percentage of sequence identity to the 16S rRNA sequence of C. minuta strain DSM32891 (SEQ ID NO:3), such as a 16S rRNA sequence having at least 90% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 99.5% identity to SEQ ID NO:3. Unless otherwise specified, such bacteria having the aforementioned percentage identities to SEQ ID NO:3, for example at least 90% identity thereto, at least 95% identity thereto, at least 96% identity thereto, at least 97% identity thereto, at least 98% identity thereto, at least 99% identity thereto, or at least 99.5% identity thereto, may be used in place of C. minuta strain DSM32891 in embodiments of the present disclosure (including the strains, methods, uses, and compositions described herein).
[0018] C. minuta strain DSM32891 or any mutant or derivative thereof may be used in any form that produces the described effects, for example, according to a preferred embodiment of the present invention, C. minuta strain DSM32891 is in the form of viable cells (culturable or non-culturable) or according to another preferred embodiment of the present invention, the strain is in the form of non-viable cells (e.g. "dead" cells that have been inactivated by any technique known in the prior art, such as but not limited to heat, freezing or ultraviolet radiation).
[0019] Another aspect of the invention relates to any of the cellular components, metabolites, secreted molecules, or combinations thereof, obtained from the strains according to the invention or from a combination of microorganisms comprising at least one strain according to the invention.
[0020] Among the cellular components of bacteria, there may be cell wall components (such as, but not limited to, peptidoglycan), nucleic acids, membrane components, or other such as proteins, lipids, carbohydrates, and combinations thereof, such as lipoproteins, glycolipids, or glycoproteins. Metabolic products include any molecules produced or modified by bacteria as a result of the metabolic activity of bacteria during growth, technological processes (such as, but not limited to, food or drug manufacturing processes), product storage, or use of the molecules during gastrointestinal passage. Examples of such metabolic products include, but are not limited to, organic and inorganic acids, proteins, peptides, amino acids, enzymes, lipids, carbohydrates, lipoproteins, glycolipids, glycoproteins, vitamins, salts, metals, or nucleic acids. Secreted molecules include any molecules transported outward or released by bacteria during bacterial growth, technological processes (such as, but not limited to, food or drug manufacturing), product storage, or use of the molecules during gastrointestinal passage. Examples of such molecules are, but are not limited to, organic and inorganic acids, proteins, peptides, amino acids, enzymes, lipids, carbohydrates, lipoproteins, glycolipids, glycoproteins, vitamins, salts, metals, or nucleic acids.
[0021] Another aspect of the present invention relates to a composition, hereinafter referred to as the "composition according to the invention", which comprises the strain according to the invention and / or any of the cellular components, metabolic products or secreted molecules of the strain according to the invention, or a combination thereof.
[0022] A composition generally defined is a set of components, which consists of at least the bacterial strain according to the invention in any concentration, or at least cellular components, metabolic products or secreted molecules of the bacterial strain according to the invention, or any combination thereof, or any combination thereof.
[0023] In a preferred embodiment, the composition according to the invention comprises 10 4 ~10 14 The composition has a concentration of the strain according to the present invention of colony forming units (CFU). The term CFU refers to the number of bacteria that can produce colonies during growth, i.e., viable bacteria. It should be understood that non-viable bacteria may also be present in the composition, and generally, such are not expected to have any adverse effect on the properties of the live bacteria in the composition, but on the contrary, they may affect themselves.
[0024] In another particular embodiment, the composition according to the invention may also comprise at least one other additional microorganism different from the strain according to the invention and / or its cellular components, metabolic products, or secreted molecules, or any combination thereof. For example, but not limited to, additional microorganisms that may form part of the composition are selected from at least one of the following groups: at least one strain of another species of the family Christensenellaceae, in particular of the genus Christensenella and in particular of the species Christensenella minuta, - at least one Lactobacillus or Bifidobacterium of intestinal, gastrointestinal or environmental origin, the Lactobacillus being selected from the list including but not limited to bacteria of the genus Bifidobacterium, Lactobacillus, Lactococcus, Enterococcus, Propionibacterium, Leuconostoc, Weissella, Pediococcus or Streptococcus. - At least one strain of other phylogenetic groups, genera, or species of prokaryotes of intestinal, gastrointestinal, or environmental origin, such as, but not limited to, Archaea, Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Verrucomicrobia, Fusobacteria, Metanobacteria, Spirochaetes, Fibrobacteres, Deferribacteres, Deinococcus, Thermus, Cianobacteria, Methanobrevibacterium, Peptostreptococcus, Ruminococcus , Coprococcus, Subdolingranulum, Dorea, Bulleidia, Anaerofustis, Gemella, Roseburia, Catenibacterium, Dialister, Anaerotruncus, Staphylococcus, Micrococcus, Propio such as nibacterium, Enterobacteriaceae, Faecalibacterium, Bacteroides, Parabacteroides, Prevotella, Eubacterium, Akkermansia, Bacillus, Butyrivibrio, or Clostridium, - at least one strain of fungus or yeast, such as, but not limited to, those belonging to the genus Saccharomyces, Candida, Pichia, Debaryomyces, Torulopsis, Aspergillus, Rhizopus, Mucor, or Penicillium.
[0025] Said additional microorganism may be a strain of the same species or a strain of a different species, or a taxon of microorganisms from the one corresponding to the strain according to the present invention.The cells contained in the composition may be viable or non-viable, and may be in any stage of development or growth state (latent phase, exponential growth phase, stationary phase, etc.), regardless of the morphology presented.In a particular embodiment, said additional microorganism comprises at least one Enterobacteriaceae or lactic acid bacteria.
[0026] Optionally, in another particular embodiment, the composition according to the invention may also comprise at least one bioactive ingredient (active substance, active ingredient, or therapeutic agent), such as, for example, an ingredient of a food, a botanical product, and / or a drug.
[0027] The term "bioactive ingredient" refers to compounds having biological activity in the field of application of this patent that may improve or complement the activity of C. minuta strain DSM32891, including food materials or ingredients (e.g., but not limited to, polyunsaturated fatty acids, conjugated linoleic acid, prebiotics, fiber, guar gum, glucomannan, chitosan, copper picolinate, calcium, etc.), other probiotics, plants, plant extracts or ingredients, and drugs.
[0028] In a particular embodiment, the composition according to the present invention is a pharmaceutical composition.A pharmaceutical composition is a set of components, which is composed of at least the strain according to the present invention, or at least the cellular components, metabolites, or secreted molecules of the strain according to the present invention, or any combination thereof, and has at least one use in improving the physical, physiological, or psychological well-being of a subject, resulting in an improvement in the overall state of health of the subject or a reduction in the risk of disease.The pharmaceutical composition can be a medicine.
[0029] The term "medicine" has a more limited meaning than the term "pharmaceutical composition" as defined in the present invention, since a medicine or drug necessarily has a preventive or therapeutic effect. The medicines referred to in relation to the present invention may be for human or veterinary use. A "human medicine" is any substance or combination of substances that is presented as having properties for the treatment or prevention of a human disease, or that may be used or administered to humans to restore, correct or modify a physiological function, to produce a pharmacological, immunological or metabolic effect, or to establish a medical diagnosis. The term "veterinary medicine" is any substance or combination of substances that is presented as having curative or preventive properties in relation to an animal disease, or that may be administered to an animal to re-establish, correct or modify its physiological function, to produce a pharmacological, immunological or metabolic effect, or to establish a veterinary diagnosis. Also considered as a "veterinary medicine" is a "medicated feed premix" prepared for incorporation into feed.
[0030] In addition to the requirement for a therapeutic effect, for which the pharmaceutical composition may require the use of other therapeutic agents, there may be additional rationales that in most cases require or recommend the use of a combination of a compound according to the invention with a biologically active ingredient, such as when an activity is claimed for the biologically active ingredient so as to constitute a medicinal product. The compound according to the invention obviously relates to the strain according to the invention, or to a strain derived therefrom, or to a cellular component, metabolite or secreted molecule obtained from the strain according to the invention, or any combination thereof.
[0031] In certain embodiments, the pharmaceutical composition also comprises at least one pharma- ceutically acceptable vehicle and / or excipient.
[0032] "Vehicle" or carrier is preferably an inert substance. The function of vehicle is to facilitate the incorporation of other compounds, to allow better dosage and administration, or to give consistency and form to pharmaceutical compositions. Exemplary carriers include cryoprotectants or cryoprotectants. Thus, vehicle is a substance used in pharmaceuticals to dilute any of the components of pharmaceutical compositions according to the present invention to a certain volume or weight, or, even without diluting the components, the vehicle can allow better dosage and administration or give consistency and form to pharmaceuticals. When the presentation form is liquid, the pharmaceutically acceptable vehicle is a diluent.
[0033] Exemplary compositions of the present disclosure include bacteria of the present disclosure, e.g., C. minuta bacterial strain DSM32891, and a "cryoprotectant" which is a substance that, when combined with the bacteria, e.g., bacteria of the present disclosure, significantly reduces its chemical and / or physical instability during dehydration (e.g., freeze-drying) and / or subsequent storage. Exemplary cryoprotectants include sugars and their corresponding sugar alcohols, such as sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, and mannitol, amino acids, such as arginine or histidine, lyotropic salts, such as magnesium sulfate, polyols, such as propylene glycol, glycerol, poly(ethylene glycol), or polypropylene glycol, and combinations thereof. Additional exemplary cryoprotectants include gelatin, dextrin, modified starch, and carboxymethylcellulose. Preferred sugar alcohols are those compounds obtained by reduction of monosaccharides and disaccharides, such as lactose, trehalose, maltose, lactulose, and maltolose. Additional examples of sugar alcohols are glucitol, maltitol, lactitol, and isomaltulose. Cryoprotectants are generally added to the formulation prior to lyophilization in a "cryoprotectant amount". This means that after lyophilization of the bacteria in the presence of a cryoprotectant amount, the bacteria retain significantly more viability (ability to form colonies upon reconstitution) than if they were dehydrated and stored in the same manner in the presence of the cryoprotectant.
[0034] An exemplary composition of the present disclosure includes a bacterium of the present disclosure, such as C. minuta bacterial strain DSM32891, and a "cryoprotectant," which is a substance used to protect the bacterium from damage during freezing and thawing. The cryoprotectant may be any additive, so long as it protects the bacterium from damage during freezing and thawing. Examples of cryoprotectants include sugars (e.g., sucrose, fructose, trehalose), polyalcohols (e.g., glycerol, sorbitol, mannitol), polysaccharides (e.g., cellulose, starch, gums, maltodextrin), polyethers (e.g., polypropylene glycol, polyethylene glycol, polybutylene glycol), antioxidants (e.g., natural antioxidants such as ascorbic acid, beta-carotene, vitamin E, glutathione, chemical antioxidants), oils (e.g., rapeseed oil, sunflower oil, olive oil), surfactants (e.g., Tween 20, Tween 80, fatty acids), peptones (e.g., , soy peptone, wheat peptone, whey peptone), tryptone, vitamins, minerals (e.g., iron, manganese, zinc), hydrolysates (e.g., protein hydrolysates from whey powder, malt extract, soy, etc.), amino acids, peptides, proteins, nucleic acids, nucleotides, nucleic acid bases (e.g., cytosine, guanine, adenine, thymine, uracil, xanthine, hypoxanthine, inosine), yeast extract (e.g., yeast extract of Saccharomyces species, Kluyvermomycesa species, or Torula species), beef extract, growth factors, and lipids.
[0035] The term "excipient" refers to a substance that aids in the preparation of a pharmaceutical composition in the sense of aiding in the absorption of any of the components of the composition according to the invention, stabilizing the components, or imparting consistency to the pharmaceutical composition or adding a flavor that makes the pharmaceutical composition more palatable. Thus, an excipient may have the function of holding the components together, such as starch, sugar, or cellulose, a sweetening function, a coloring function, a protection function for the pharmaceutical, such as isolating the pharmaceutical from air and / or moisture, a filler function for pills, capsules, or other presentation forms, such as dibasic calcium phosphate, a disintegrant function that promotes the dissolution of the component in the intestine and its absorption, and does not exclude other types of excipients not mentioned in this paragraph. Thus, the term "excipient" is defined as a material contained in a galenical form that is added to an active ingredient or its related to enable its preparation and stability, modify its organoleptic properties, or determine the physicochemical properties of the pharmaceutical composition and its bioavailability. A "pharmaceutical acceptable" excipient must enable the activity of the compound of the pharmaceutical composition, i.e., be compatible with the component.
[0036] Additionally, as will be appreciated by those of skill in the art, excipients and vehicles, if present, must be pharmacologically acceptable, i.e., they must be approved and evaluated so as not to cause injury to the organism to which they are administered.
[0037] The pharmaceutical composition or medicament may be presented in any clinically approved dosage form and therapeutically effective amount. For example, the pharmaceutical composition or medicament may be in a form suitable for oral, sublingual, nasal, intrathecal, bronchial, rectal, transdermal, inhalation, or parenteral administration, preferably in a form suitable for oral administration. The pharmaceutical composition according to the present invention may be formulated in a solid, semi-solid, liquid, or gas form, such as a tablet, capsule, powder, pellet, ointment, solution, suppository, injection, inhalant, gel, microbead, or aerosol. The form suitable for oral administration is selected from the list including, but not limited to, drops, syrups, tisanes, elixirs, suspensions, instant suspensions, drinkable vials, tablets, capsules, pellets, cachets, pills, tablets, troches, lozenges, or lyophilized forms. In a particular embodiment, the composition according to the present invention is presented in a form suitable for oral, sublingual, nasal, bronchial, lymphatic, rectal, transdermal, inhalation, or parenteral administration.
[0038] In a more specific embodiment, the composition according to the present invention is presented in a form suitable for oral administration.The form suitable for oral administration refers to a physical state that can allow oral administration.The form suitable for oral administration is selected from the list including, but not limited to, drops, syrups, tisanes, elixirs, suspensions, instant suspensions, drinkable vials, tablets, capsules, pellets, cachets, pills, caplets, lozenges, lozenges, or lyophilized forms.
[0039] A "galenical form" or "pharmaceutical form" is an arrangement in which active ingredients and excipients are adapted to form a medicinal product. It is defined as a combination of the form in which a pharmaceutical composition is presented by the manufacturer and the form in which said pharmaceutical composition is administered. In the present invention, the expression "effective amount" or "therapeutically effective amount" refers to the amount of the components of a pharmaceutical composition that, when administered to a mammal, preferably a human, is sufficient to bring about the prevention and / or treatment, as defined below, of a disease or pathological condition of interest in a mammal, preferably a human. The therapeutically effective amount will vary, for example, depending on the activity of the strain according to the present invention, the cellular components in any presentation form, the metabolites, the secreted molecules, or any combination thereof, and the therapeutically effective amount will also vary depending on the metabolic stability and duration of action of the compound, the age, weight, general health, sex, and diet of the patient, the method and time of administration, the rate of excretion, the drug combination, the severity of the particular disorder or pathological condition, and the subject to be treated, but can be determined by a person skilled in the art according to his or her own knowledge and this description.
[0040] As an alternative to a pharmaceutical composition, the composition according to the invention may also be a nutritional composition.
[0041] The term "nutritional composition" according to the present invention refers to a foodstuff that provides nutrients to the subject ingesting the nutritional composition and at the same time beneficially affects one or more functions of an organism so as to provide better health and wellness. Thus, the nutritional composition may be intended for the prevention and / or treatment of disease or disease-causing factors. Thus, the term "nutritional composition" according to the present invention can be used as a synonym for functional foodstuff or foodstuff for a specific nutritional purpose or medicinal foodstuff.
[0042] In certain embodiments, the nutritional composition is a foodstuff, a supplement, a nutraceutical, a probiotic, or a synbiotic.
[0043] In a more particular embodiment, the food product is selected from the list including dairy products, plant products, meat products, aperitifs, chocolates, beverages, or baby food. The dairy product is selected from the list including but not limited to products derived from fermented milk (such as but not limited to yogurt or cheese) or non-fermented milk (such as but not limited to ice cream, butter, margarine, whey). The plant product is for example but not limited to cereals in any presentation form, whether fermented or not. The beverage can be but is not limited to fruit juice or non-fermented milk.
[0044] The term "supplement" is a synonym of any of the terms "health supplement", "nutritional supplement" or "food supplement" and is a "food ingredient" intended to supplement nutrition. Some examples of health supplements are, but are not limited to, vitamins, minerals, botanical products, amino acids, and food ingredients such as enzymes and glandular extracts. The supplement is presented as a supplement to the diet, rather than as a replacement for conventional food products or as a single component of a meal or diet.
[0045] The term "nutraceutical" as used herein refers to a substance isolated from foodstuffs and used in dosage form that has a beneficial effect on health.
[0046] As used herein, the term "probiotic" refers to live microorganisms that, when provided in suitable amounts, promote a health benefit in the host organism.
[0047] The term "synbiotics" as used in the present invention refers to those foodstuffs that contain a mixture of prebiotics and probiotics. In principle, the foodstuffs contain a prebiotic component that promotes the growth and / or metabolic activity and ultimately the effect of the probiotics with which they are combined, for example the possible association of bifidobacteria with fructooligosaccharides or galactooligosaccharides.
[0048] Another aspect of the present invention refers to the use of a bacterial strain according to the invention, or a component derived therefrom, or a composition according to the invention, for the manufacture of a pharmaceutical, a nutritional composition, or a foodstuff.
[0049] Another aspect of the invention relates to the C. minuta strain DSM32891, any of the cellular components, metabolites, secreted molecules or combinations thereof obtained from the strain according to the invention, or the composition according to the invention, for use as a medicament. The term medicament has been defined previously and applies to this aspect of the invention.
[0050] In another aspect, the present invention relates to a bacterial strain according to the invention, a strain derived therefrom, a cellular component, a metabolite, a secreted molecule, or a combination thereof obtained from a bacterial strain according to the invention, or a composition according to the invention, for use in the prevention and / or treatment of mood disorders (such as depression), stress disorders, and anxiety disorders.
[0051] In the present invention, the term "treatment" refers to combating the effects caused as a result of a disease or pathological condition of interest in a subject (preferably a mammal, more preferably a human), and includes: (i) inhibiting, i.e., delaying the onset of, a disease or pathological condition; (ii) alleviating the disease or pathological condition, i.e. causing the regression of the disease or pathological condition or its symptoms; (iii) stabilizing a disease or pathological condition;
[0052] In the present invention, the term "prevention" refers to preventing the occurrence of a disease, i.e., preventing a disease or pathological condition from occurring in a subject, preferably a mammal, more preferably a human, especially when the subject has a predisposition to the pathological condition.
[0053] In the present invention, mood disorders or disturbances include, but are not limited to, depression, major depression, atypical depression, typical or melancholic depression, psychogenic depression, catatonic depression, perinatal depression, bipolar disorder, seasonal affective disorder, dysthymia, depressive personality disorder, dual depression, unspecified depressive disorder, recurrent brief depressive disorder, minor depression, mood disorders induced by substance abuse or by drug use, etc.
[0054] The exemplary method of the present disclosure provides for the prevention or treatment of disorders related to trauma and stressor-related disorders, in which exposure to traumatic or stressful events is explicitly stated as a diagnostic criterion. Such disorders are referred to herein as "stress disorders", and include, for example, reactive attachment disorder, disinhibited social engagement disorder, post-traumatic stress disorder (PTSD), acute stress disorder, and adjustment disorder.
[0055] The methods of the present disclosure also provide for the prevention or treatment of anxiety disorders, such as panic attacks, panic disorder, agoraphobia, social phobia or social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder (ASD), generalized anxiety disorder, or acute stress disorder.
[0056] Without intending to be limited by theory, the aforementioned stress and anxiety disorders are believed to be characterized by altered levels of epinephrine, norepinephrine, serotonin, and / or dopamine, and it is expected that the modulatory effects of the C. minuta strain DSM32891 of the present invention on these hormones will treat, ameliorate, or alleviate these conditions or one or more of their symptoms.
[0057] Subjects amenable to treatment according to the present invention include mammalian subjects, including humans, suffering from or at risk of any of the various disorders disclosed herein, including mood disorders (such as depressive disorders), anxiety disorders, and stress disorders. Within the scope of the present method, C. minuta strain DSM32891 or a composition comprising C. minuta strain DSM32891 is administered in an amount effective to treat a particular disorder, alone or in combination with a psychotropic drug, including but not limited to the general classes of drugs: antidepressants, mood stabilizers, anxiolytics, anticonvulsants, antipsychotics, antiaddictive drugs, appetite suppressants, and opiate agonists. (See, for example, R J. Baldessarini in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 18, McGraw-Hill, 1996).
[0058] The disclosed methods can be used to treat or prevent disorders in humans or non-human animals. Exemplary non-human animals include, but are not limited to, pets, livestock animals, zoo animals, mammals, and the like, such as dogs, cats, guinea pigs, ferrets, hamsters, pigs, cows, goats, sheep, horses, mice, rats, and the like.
[0059] The treatment or prevention of the disorder may comprise the administration of an effective amount of C. minuta strain DSM32891. The amount of bacteria administered may be 10 4 ~10 14 The effective amount may contain 10 colony forming units (CFU) per gram or milliliter of final composition. The effective amount may be determined based on factors known to those skilled in the art, including, but not limited to, age, weight, sex, and the type and severity of the disorder. When the bacteria is administered in a composition, the composition may contain 10 4 ~10 14 having a concentration of colony forming units (CFU) bacteria.
[0060] In another aspect, the present invention relates to any of the strains according to the invention, strains derived from strains according to the invention, cellular components, metabolites, secreted molecules, or combinations thereof obtained from the strains according to the invention, or compositions according to the invention, for use as an adjuvant in the treatment or prevention of mood disorders (such as depression), stress disorders, and anxiety disorders.
[0061] In exemplary embodiments, the bacteria or composition thereof for use may be for administration in any clinically approved dosage form and therapeutically effective amount. For example, the bacteria or composition thereof may be for oral, sublingual, nasal, intrathecal, bronchial, rectal, transdermal, inhalation, or parenteral administration, preferably oral administration. The pharmaceutical composition according to the invention may be formulated in a solid, semi-solid, liquid, or gas form, such as a tablet, capsule, powder, pellet, ointment, solution, suppository, injection, inhalant, gel, microbead, or aerosol. A form suitable for oral administration is selected from the list including, but not limited to, drops, syrups, tisanes, elixirs, suspensions, extemporaneous suspensions, drinkable vials, tablets, capsules, pellets, cachets, pills, tablets, troches, lozenges, or lyophilized forms. In certain embodiments, the composition according to the invention is presented in a form suitable for oral, sublingual, nasal, bronchial, lymphatic, rectal, transdermal, inhalation, or parenteral administration and / or is administered by such a route of administration. A preferred route of administration delivers C. minuta strain DSM32891 or a composition thereof to the gastrointestinal tract, for example by oral, sublingual, or rectal administration.
[0062] In a more specific embodiment, the composition according to the present invention is presented in a form suitable for oral administration and / or is administered orally.The form suitable for oral administration refers to a physical state that can allow oral administration.The form suitable for oral administration is selected from the list including, but not limited to, drops, syrups, tisanes, elixirs, suspensions, instant suspensions, drinkable vials, tablets, capsules, pellets, cachets, pills, caplets, lozenges, lozenges, or lyophilized forms.
[0063] In the present invention, an "adjuvant" is understood to help improve the effectiveness or efficiency of other medicinal products for the treatment of mood disorders (such as depression), stress and anxiety disorders, and migraine, reducing the dose and / or frequency of their administration, or increasing their efficacy by administration of a combination of strains according to the invention, by mechanisms having complementary action.
[0064] In another aspect, the present invention relates to a strain according to the present invention, a strain derived from a strain according to the present invention, a cellular component, a metabolite, a secreted molecule, or a combination thereof obtained from a strain according to the present invention, or a composition according to the present invention, for the preparation of a foodstuff. The term pharmaceutical product has been previously defined in the description and applies to this aspect of the invention. In an exemplary embodiment, the present disclosure provides an isolated bacterium of the strain of Christensenella minuta having the deposit number DSM32891.
[0065] In an exemplary embodiment, the disclosure provides an isolated bacterium of a strain derived from the strain of Christensenella minuta having deposit number DSM 32891. In an exemplary embodiment, the disclosure provides an isolated bacterium comprising a genetically modified mutant of the strain of Christensenella minuta having deposit number DSM 32891 or a strain derived therefrom.
[0066] The isolated bacteria may be viable or non-viable.
[0067] In exemplary embodiments, the disclosure provides cellular components, metabolic products, secreted molecules, or any combination thereof obtained from the bacteria described herein.
[0068] In an exemplary embodiment, the disclosure provides a composition comprising bacteria of a strain of Christensenella minuta having the deposit number DSM32891. The composition may also comprise at least one bioactive ingredient. The composition may comprise at least one microorganism that is a different strain from the bacteria, which may be an enterobacterium or a lactic acid bacterium. The composition may be a pharmaceutical composition. The composition may further comprise at least one pharmaceutically acceptable vehicle and / or excipient. The composition may be presented in a form suitable for oral, sublingual, nasal, bronchial, lymphatic, rectal, transdermal, inhalation, or parenteral administration. The composition may be a nutritional composition. The composition may be a foodstuff, a supplement, a nutraceutical, a probiotic, or a synbiotic. The foodstuff may be selected from the list consisting of a dairy product, a plant product, a meat product, an aperitif, a chocolate, a beverage, or a baby food. The composition may comprise at least 10 per gram or milliliter of final composition. 4 ~10 14 The bacterial concentration may be in the range of 0.01 to 0.15 colony forming units (CFU).
[0069] The bacteria may be lyophilized, and the composition may optionally include a cryoprotectant such as a sugar, sugar alcohol, amino acid, or polyol. The cryoprotectant may include a sugar or sugar alcohol such as sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, mannitol, lactulose, maltulose, glucitol, maltitol, lactitol, or isomaltulose, an amino acid such as arginine or histidine, a lyotropic salt such as magnesium sulfate, a polyol such as propylene glycol, glycerol, poly(ethylene glycol), or propylene glycol, or gelatin, dextrin, dextran, modified starch, carboxymethylcellulose, or hydroxypropyl-beta-cyclodextrin, or a combination thereof.
[0070] The pharma- ceutically acceptable vehicle and / or excipient may be a cryoprotectant such as glycerol, or a sugar such as sucrose, fructose, trehalose, sugar alcohols such as glycerol, sorbitol, mannitol, polysaccharides such as cellulose, starch, gums, maltodextrin, polyethers such as polypropylene glycol, polyethylene glycol, polybutylene glycol, antioxidants such as ascorbic acid, beta carotene, vitamin E, natural antioxidants such as glutathione, chemical antioxidants, oils such as rapeseed oil, sunflower oil, olive oil, T The cryoprotectants may include surfactants such as Tween 20, Tween 80, fatty acids, peptones such as soy peptone, wheat peptone, whey peptone, tryptone, vitamins, minerals such as iron, manganese, zinc, hydrolysates such as protein hydrolysates such as whey powder, malt extract, soybean, amino acids, peptides, proteins, nucleic acids, nucleotides, nucleic acid bases such as cytosine, guanine, adenine, thymine, uracil, xanthine, hypoxanthine, inosine, yeast extract, beef extract, growth factors, lipids, and combinations thereof.
[0071] In an exemplary embodiment, the disclosure provides a bacterium or a composition as disclosed herein for use as a medicament.
[0072] In an exemplary embodiment, the present disclosure provides a method of treatment comprising administering an isolated bacterium or composition as disclosed herein to a subject in need thereof.
[0073] In an exemplary embodiment, the disclosure provides an isolated bacterium or a composition as disclosed herein for use in the prevention and / or treatment of a mood disorder.
[0074] In an exemplary embodiment, the present disclosure provides a method for the prevention and / or treatment of a mood disorder comprising administering an effective amount of an isolated bacterium or composition as disclosed herein.
[0075] In an exemplary embodiment, the disclosure provides an isolated bacterium or composition as disclosed herein for use as an adjuvant in the treatment of altered mental status.
[0076] A method of treating and / or preventing an altered mental state comprising administering an effective amount of an isolated bacterium or composition as disclosed herein.
[0077] The mood disorder may be selected from the list including depression, major depression, atypical depression, typical or melancholic depression, psychogenic depression, catatonic depression, perinatal depression, bipolar disorder, seasonal affective disorder, dysthymia, depressive personality disorder, dual depression, unspecified depressive disorder, recurrent brief depressive disorder, minor depression, altered mental status, and mood disorder induced by substance abuse or by the use of a substance such as a drug of abuse.
[0078] In an exemplary embodiment, the disclosure provides for the use of an isolated bacterium or composition as disclosed herein for the preparation of a food product.
[0079] In an exemplary embodiment, the present disclosure provides a method of making a food product comprising mixing the isolated bacteria or compositions as disclosed herein.
[0080] In an exemplary embodiment, the disclosure provides an isolated bacterium or a composition as disclosed herein for use in the prevention and / or treatment of a stress disorder.
[0081] In an exemplary embodiment, the disclosure provides a method of treating or preventing a stress disorder comprising administering an effective amount of an isolated bacterium or composition as disclosed herein.
[0082] The stress disorder may be selected from reactive attachment disorder, disinhibited social engagement disorder, post-traumatic stress disorder (PTSD), acute stress disorder, and adjustment disorder.
[0083] In an exemplary embodiment, the disclosure provides an isolated bacterium or a composition as disclosed herein for use in the prevention and / or treatment of an anxiety disorder.
[0084] In an exemplary embodiment, the disclosure provides a method of treating or preventing an anxiety disorder, comprising administering an effective amount of an isolated bacterium or composition as disclosed herein.
[0085] The anxiety disorder may be selected from panic attacks, panic disorder, agoraphobia, social phobia or social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder (ASD), generalized anxiety disorder, or acute stress disorder.
[0086] In an exemplary embodiment, the disclosure provides an isolated bacterium or a composition as disclosed herein for use as a medicament.
[0087] In an exemplary embodiment, the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof comprising administering an effective amount of an isolated bacterium or composition as disclosed herein.
[0088] In exemplary embodiments, the disclosure provides Christensenellaceae bacteria, particularly isolated Christensenellaceae bacteria, or compositions comprising Christensenellaceae bacteria, for use in the prevention and / or treatment of mood disorders, stress disorders, anxiety disorders, and / or migraines.
[0089] In an exemplary embodiment, the present disclosure provides a method of treating or preventing a mood disorder, a stress disorder, an anxiety disorder, and / or a migraine headache comprising administering an effective amount of a bacteria or composition as disclosed herein.
[0090] In an exemplary embodiment, the disclosure provides a Christensenellaceae bacterium or a composition comprising a Christensenellaceae bacterium for use as an adjuvant in the treatment of mood disorders and / or stress disorders and / or anxiety disorders and / or migraines.
[0091] In an exemplary embodiment, the present disclosure provides a method for treating or preventing mood disorders and / or stress and / or anxiety comprising administering an effective amount of a bacteria or composition as disclosed herein.
[0092] The mood disorder may be selected from the list including depression, major depression, atypical depression, typical or melancholic depression, psychogenic depression, catatonic depression, perinatal depression, bipolar disorder, seasonal affective disorder, dysthymia, depressive personality disorder, dual depression, unspecified depressive disorder, recurrent brief depressive disorder, minor depression, altered mental status, mood disorder induced by substance abuse or by the use of a substance such as a drug of abuse.
[0093] In the methods and uses disclosed herein, the Christensenellaceae bacterium can be a bacterium of the genus Christensenella. The Christensenella bacterium can be selected from the species Christensenella minuta, Christensenella timonensi, Christensenella massiliensis, or any combination thereof. The Christensenella bacterium can be a Christensenella massiliensis strain with deposit number DSM102344, or a Christensenella timonensis strain with deposit number DSM102800. The Christensenella bacterium can be a Christensenella minuta strain DSM32891, or a derivative or mutant thereof, or a Christensenella minuta strain with deposit number DSM22607, or a derivative or mutant thereof, or any combination thereof.
[0094] In the methods and uses disclosed herein, the Christensenellaceae bacteria may be in the form of viable and / or non-viable cells.
[0095] In the methods and uses disclosed herein, the Christensenellaceae bacterium may comprise a 16S rRNA sequence having at least 90% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 99.5% identity to the 16S rRNA sequence of a strain of Christensenella minuta having deposit number DSM 32891 (SEQ ID NO: 3), or may comprise a strain of Christensenella minuta having deposit number DSM 32891.
[0096] The methods and uses disclosed herein can be for use in subjects selected from humans or non-human animals.Exemplary non-human animals include pets, livestock animals, zoo animals, mammals, dogs, cats, guinea pigs, ferrets, hamsters, pigs, cows, goats, sheep, horses, mice, and rats.
[0097] In the methods and uses disclosed herein, 10 of the Christensenellaceae bacteria 4 ~10 14 and, particularly when the Christensenellaceae bacteria are administered in a composition, the composition may comprise administration of 10 colony forming units (CFU) per gram or milliliter of final composition. 4 ~10 14 The concentration of bacteria is 0.01 mg / mL.
[0098] Throughout the description and claims, the word "comprises" and variations thereof are not intended to exclude other technical features, additives, ingredients, or steps. Other objects, advantages, and features of the present invention will be apparent to those skilled in the art, in part from the description, and in part from the practice of the present invention. The following examples and figures are provided by way of illustration and are not intended to limit the present invention. [Brief description of the drawings]
[0099] [Figure 1]Evaluation of the effect of administration of B. breve MF217 (1 × 109 CFU / day) and C. minuta DSM32891 (1 × 109 CFU / day) in C57BL / 6 mice (n = 10 / group) exposed to acute social stress in the sucrose preference test (SPF). Data are expressed in grams with mean and standard error. Statistically significant differences were established by applying ANOVA on factors followed by post hoc Bonferroni tests (* = p < 0.05, ** = p < 0.01). C, control mice; S, mice subjected to acute stress and without treatment; S + B. breve, mice subjected to acute stress and treated with B. breve; S + C. min, mice subjected to acute stress and treated with C. minuta. [Diagram 2] Evaluation of the effect of administration of B. breve MF217 (1x109 CFU / day) and C. minuta DSM32891 (1x109 CFU / day) in C57BL / 6 mice (n=10 / group) exposed to acute social stress in the tail suspension test (TST). Data are expressed as the mean and its standard error of time (sec). Statistically significant differences were established by applying ANOVA on the factors followed by a post hoc Bonferroni test (***=p<0.001). C, control mice; S, mice subjected to acute stress and without treatment; S+B.bre, mice subjected to acute stress and treated with B.breve; S+C.min, mice subjected to acute stress and treated with C.minuta. [Figure 3A-3D]Evaluation of the effect of administration of C. minuta DSM32891 (1 × 109 cfu / day) in C57BL / 6 mice exposed to social stress on stress markers in plasma. Data are expressed in nM with mean and standard error. Statistically significant differences were established by applying one factor ANOVA followed by Bonferroni post-hoc test (*=p<0.05, **=p<0.001, ***=p<0.001). C, control mice; S, untreated mice subjected to stress; S+M, mice subjected to stress and treated with C. minuta. Stress markers were measured 1 day before social defeat, 1 day after the onset of social defeat, and 10 days after the onset of social defeat. Results are shown for adrenaline (Figure 3A), noradrenaline (Figure 3B), serotonin (Figure 3C), and dopamine (Figure 3D). EXAMPLES
[0100] The invention will now be illustrated by several tests that demonstrate the properties and effectiveness of exemplary products according to the invention. These examples are intended to illustrate, rather than limit, the invention, which is limited only by the claims.
[0101] Example 1 Isolation and Identification of Christensenella Species The biological material that was the object of this patent was isolated from feces of healthy volunteers, processed and inoculated into a Gut Microbiota Medium (GMM), the composition of which is based on the medium recommended in previous publications
[18] ,
[19] , with modifications designed by the inventor. The modifications consisted of fermenting the processed feces for 24 hours in an anaerobic chamber, while maintaining a constant pH. The fermented GMM medium was used as a supplement to a very delicate anaerobic agar (FAA) medium containing 0.5% defibrinated blood, which was used to inoculate serial dilutions of the feces and isolate colonies, after incubating the plates for 72 hours at 37 °C in an anaerobic chamber. Christensenella minuta DSM32891 was isolated from the colonies that grew out.
[0102] Identification was performed by sequencing the 16S rRNA gene (1.26 Kb) using 27f (SEQ ID NO: 1: 5'-AGAGTTTGATCCTGGCTCAG-3') and 1401r (SEQ ID NO: 2: 5'-CGGTGTGTACAAGACCC-3') primers by Sanger sequencing technology on an ABI 3730XL sequencer. By comparing the obtained sequence with sequences in the NCBI database and the BLASTn algorithm, the isolated strain DSM32891 was identified as the species Christensenella minuta with an identity percentage of 100%. The complete sequence (SEQ ID NO: 3) is shown below: >16S rRNA gene sequence of Christensenella minuta DSM32891
[0103] Example 2. Effect of C. minuta strain DSM32891 in an animal model of social stress-induced depression. Development and sampling of an acute social stress animal model Adolescent male C57BL / 6 mice (32 days old, Charles River, Les Oncins, France) were used in this study. The mice were maintained at temperature (23 o The mice were kept in controlled conditions of ambient temperature (C), relative humidity (40-50%), and a 12-h light / dark cycle and fed a standard diet (D12450K, Research diet, Brogaarden, Denmark) for 11 weeks (during the first week, the mice were isolated in a prepared room to prevent possible zoonotic infections). The mice were randomly divided into four experimental groups (n=10). The control group (C), the stress group (S), the group treated with Christensenella minuta DSM32891 (S+C.min), and the group treated with Bifidobacterium breve MF217 (S+B.breve) were used for comparison purposes. The mice in the S+C.min group were fed with the bacterial strain according to the invention (1x10 9 The S+B. breve group was treated with oral administration of B. breve (1x10 colony-forming units [CFU]) suspended in 10% skim milk. 9 The mice were treated with a dose of 100 mg of 1000 mg of colony-forming units [CFU] of 100 mg ...
[0104] Acute social stress model To induce acute social stress, we used a model of social defeat in animals based on the resident-intruder paradigm
[20] . In this model, one of the two animals (the resident) was allowed to establish a territory in his cage. Then, a laboratory mouse (the intruder), in this case a C57BL / 6 male, was introduced into the cage of the resident mouse, one at a time. To do this, we used adult (4 weeks old) males of the aggressive CD-I strain (Charles River, Les Oncins, France), previously isolated and trained to be more aggressive (as resident aggressors). For four consecutive days, agonistic encounters were performed (introducing a non-experimental mouse into the resident cage for 10 min), allowing physical contact between the mice, and the intruder mouse suffered a high level of stress (reflected by the production of high levels of corticosterone). The agonistic encounters were performed in a neutral room, not in the animal facility where the mice were usually kept. Laboratory mice (intruders) exhibited escape or flight behaviors, and also defensive / submissive behaviors, after an enemy aggression (threat / attack). The criterion employed to define whether an animal was defeated was the adoption of a specific posture indicative of defeat. This posture is characterized by an upright submissive posture with limp front legs, head tilted upwards, and retracted ears
[21] .
[0105] A control group was not exposed to social defeat, but all mice in this group were introduced for 10 min into a cage identical to the one used to perform the agonistic encounters, during which they explored the cage without coming into contact with any opponent.
[0106] Before performing the agonistic encounter, animals were fasted for 12 h. Immediately after social defeat, animals were exposed to food, water, and water containing 3% sucrose for 2 h.
[0107] 3% sucrose preference test (SPT) A 3% sucrose preference test was conducted to evaluate anhedonic / anhedonic behaviors associated with depression. Anhedonic behavior (the inability to feel pleasure) is considered one of the most obvious symptoms of depression
[22] . Different animal studies have shown that depressed animals consume less than 3% sucrose water, which is considered anhedonic behavior.
[0108] The test consisted of depriving animals of water for 12 hours and then exposing them to two choices: water or water containing 3% dissolved sucrose. The sucrose and water bottles were exchanged during the 2-hour test period to ensure that there were no effects related to place preference. The amount of 3% sucrose ingested during these 2 hours would indicate anhedonic / anhedonic behavior. A lower intake of sucrose would indicate anhedonia. Sucrose preference was calculated as the percentage of sucrose ingested relative to the total amount of liquid consumed and corrected for body weight.
[0109] The results (Figure 1) show that stressed animals (S) consume significantly less 3% sucrose than control mice (C) (p<0.01), indicating anhedonia and therefore depressive behavior. Treating stressed mice with B. breve (S+B. bre) partially ameliorates anhedonia, but this improvement is not significant. However, treating stressed mice with C. minuta (S+C. min) completely ameliorates depressive behavior (p<0.05), indicating a greater effect compared to B. breve.
[0110] Tail suspension test Mice were suspended from the edge of a table by adhesive tape attached approximately 1 cm from the tip of the tail in a position where the mouse could neither escape nor hang on a nearby surface. Behavior aimed at escape attempts was quantified, as was immobility time for 5 min. The duration of immobility (as a measure of disengagement) was recorded for the 5 min that the trial lasted. This test is commonly used to assess depressive behavior in mice
[21] .
[0111] The results (Figure 2) show that stressed animals (S) remain immobile for a significantly longer time compared to the time the mouse is moving (p<0.001), whereas control mice (C) show no significant difference. This indicates a depressive behavior, since the animal does not try to escape, gives up and has little motivation to survive. Treating stressed mice with B. breve (S+B. bre) does not improve this depressive behavior, maintaining a significant difference between the immobile time and the time the mouse is moving (p<0.001). However, treating stressed mice with C. minuta (S+C.min) improves this depressive behavior and reduces the time the mouse is immobile, so the difference between both measures is smaller and not significant.
[0112] These results demonstrate that oral treatment with C. minuta exhibits greater efficacy in improving depressive behavior in an acute social stress-induced depression model compared with possible conventional probiotics such as B. breve.
[0113] The results of both tests demonstrate for the first time that treatment with C. minuta improves depressive behavior in mice exposed to acute social stress. The data demonstrate that C. minuta is a better choice as a treatment for improving mood disorders, including depressive behavior, than traditional probiotics.
[0114] Example 3. Effect of strain C. minuta DSM32891 on stress markers in an animal model of social stress-induced depression. This example reports the effects of C. minuta DSM32891 on stress markers in an animal model of social stress and depression (10 days).
[0115] Male C57BL / 6 mice were used in this study (Charles River, Les Oncins, France). Mice were maintained under controlled temperature (23°C), relative humidity (40–50%), and a 12-h light / dark cycle and fed a standard diet (D12450K, Research diet, Brogaarden, Denmark). Mice were randomly divided into three experimental groups (n=15 / group). The three groups were a control group (C), an untreated stressed group (S), and a stressed group treated with Christensenella minuta DSM32891 (S+M).
[0116] Mice in the S+M group received 1x10 9 Mice in groups C and S were treated daily with oral administration of 100 mg of 10000 colony-forming units (CFU) of 1000 mg ...
[0117] Treatment of stressed mice with C. minuta or placebo was performed for 38 days. The social defeat protocol (10 days) was started 2 weeks after treatment. The model used was adapted from the resident-intruder paradigm
[20] , shortening the encounter time to 5 min. Adult males (4 weeks old) of the CD-I strain were used as aggressive mice (Charles River, Les Oncins, France), which were previously isolated and trained to be more aggressive. For 10 consecutive days, agonistic encounters (introduction of an aggressive mouse into the resident cage for 5 min) were performed, allowing physical contact between them, and the resident mice suffered a high degree of stress. The agonistic encounters were performed in a neutral room, not in the animal room where they were usually housed. The experimental mice showed avoidance or flight behaviors, as well as defensive / submissive behaviors, after receiving an aggression (threat / attack) on the part of their opponent. The criterion used to define that an animal had been defeated was the adoption of a specific posture that signified defeat. It is characterized by a vertical, submissive posture with relaxed forelegs, head tilted upwards, and ears retracted.
[21]
[0118] A control group was not exposed to social defeat, but all mice in this group were placed for 5 min in the same cage as the mice used to carry out the agonistic encounters. They were allowed to explore the cage for 5 min without coming into contact with any opponent.
[0119] After 38 days, the mice were sacrificed by cervical dislocation and blood samples were taken.
[0120] Blood samples were tested for adrenaline, noradrenaline, serotonin, and dopamine levels at baseline before social stress, 4 h after the agonistic encounter on social stress day 1, and 4 h after the agonistic encounter on social stress day 10. Results are shown in Figures 3A-3D, and within each experimental group (C: control, S: stressed animals treated with placebo, or S+M: stressed animals treated with C. minuta), results are shown from left to right for the baseline (pre-stress), day 1 (1 day after social defeat), and day 10 (10 days after social defeat) time points.
[0121] The results show that stressed animals (S) presented increased adrenaline levels in the blood 10 days after social defeat (Figure 3A). Treatment with C. minuta prevented this increase in adrenaline levels. A similar trend was observed in noradrenaline levels (Figure 3B).
[0122] Furthermore, stressed animals (S) showed a decrease in serotonin levels in the blood 10 days after social defeat (Figure 3C). Treating stressed mice with C. minuta (S+M) not only prevented the decrease in serotonin levels in stressed mice, but also increased serotonin levels 10 days after stress compared to untreated stressed mice. Treating stressed mice with C. minuta also significantly increased dopamine levels in the blood (Figure 3D). This was not observed in either control or untreated stressed mice.
[0123] These results demonstrate that treatment with C. minuta is effective in suppressing the effects of stress on the increase of certain markers (adrenaline, noradrenaline) and in increasing blood levels of serotonin and dopamine during stress.
[0124] Example 4. Sequence characterization of C. minuta strain DSM32891 In this example, we describe the genome sequence of C. minuta strain DSM32891 and its comparison with other strains of other bacteria belonging to the family Christensenellaceae.
[0125] Genomic comparisons were performed using the Genome-to-Genome Distance Calculator v2.1 Formula2
[25] to determine the digital DNA-DNA hybridization (dDDH) score between each strain and C. minuta strain DSM32891. If dDDH is greater than 70%, the strains belong to the same species. If dDDH is greater than 79%, the strains belong to the same species and subspecies. If dDDH is 100%, the strains are identical
[26] . [Table 1]
[0126] This analysis, shown in the table above, demonstrates that the dDDH of strain DSM32891 is less than 70% of that of strains C. timonensis and C. massiliensis, confirming that they belong to different species, which is consistent with the fact that DSM32891 belongs to the species Christensenella minuta.
[0127] It also shows that strains DSM32891 and DSM22607 have dDDH of 96.5% and above 79%, respectively, indicating that they belong to the same subspecies but are different strains.
[0128] This confirms that strain DSM32891 is a novel strain belonging to the species Christensenella minuta.
[0129] References 1.Gustavsson,A.,et al.,Cost of disorders of the brain in Europe 2010.Eur Neuropsychopharmacol,2011.21(10):p.718-79. 2. Larners, F., et al., Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression.Mol Psychiatry, 2013.18(6):p.692-9. 3. Milaneschi Y, LF, Bot M, Drent ML, Penninx BW, Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression..Biol Psychiatry.,2017.May 1;81(9):p.807-814. 4.Zhernakova, A., et al., Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity.Science, 2016.352(6285):p.565-9. 5. McDonald, D., et al., American Gut:an Open Platform for Citizen Science Microbiome Research.mSystems, 2018.3(3). 6.Aizawa,E.,et al.,Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder.J Affect Disord,2016.202:p.254-7. 7.Jiang,H.,et al.,Altered fecal microbiota composition in patients with major depressive disorder.Brain Behav Immun,2015.48:p.186-94. 8.Kelly,J.R.,et al.,Transferring the blues:Depression-associated gut microbiota induces neurobehavioural changes in the rat.J Psychiatr Res,2016.82:p.109-18. 9.Naseribafrouei A,H.K.,Avershina E,Sekelja M,Linlokken A,Wilson R,Rudi K.,Correlation between the human fecal microbiota and depression.Neurogastroenterol Motil.,2014.Aug;26(8):p.1155-62. 10.Gibson-Smith,D.,et al.,The role of obesity measures in the development and persistence of major depressive disorder.J Affect Disord,2016.198:p.222-9. 11.De Palma,G.,et al.,Microbiota and host determinants of behavioural phenotype in maternally separated mice.Nat Commun,2015.6:p.7735. 12.Sanz,Y,Bifidobacteria in foods:health effects,in The Encyclopedia of Food and Health.B.Caballero,P.Finglas,and F.Toldra,Editors.Oxford Academic Press:Oxford,2016:p.p.388-394. 13.Dinan,T.G.and J.F.Cryan,Mood by microbe:towards clinical translation.Genome Med,2016.8(1):p.36. 14.Romijn,A.R,et al,A double-blind,randomized,placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression.Aust N Z J Psychiatry,2017.51(8):p.810-821. 15.Pinto-Sanchez,M.l,et al.,Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity:A Pilot Study in Patients With Irritable Bowel Syndrome.Gastroenterology,2017.153(2):p.448-459 e8. 16.Yu,M,et al.,Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC / MS-based metabolomics.J Pharm Biomed Anal,2017.138:p.231-239. 17.I.Mironova,I.Z.,N.Zhukova,V.Alifirova,A.Latypova,O.Izhboldina,M.Nikitina,V.Petrov,M.Titova,Affective disorders and microbiome in patients with Parkinson’s disease(PR2063).European Journal of Neurology,2017.24(Suppl.1),:p.445-678. 18.Gibson GR,C.J.,Macfarlane GT.,Use of a three-stage continuous culture system to study the effect of mucin on dissimilatory sulfate reduction and methanogenesis by mixed populations of human gut bacteria.Appl Environ Microbiol.1988 Nov;54(ll),1988.Nov;54(11):p.2750-5. 19.Lesmes,U.,et al.,Effects of resistant starch type III polymorphs on human colon microbiota and short chain fatty acids in human gut models.J Agric Food Chem,2008.56(13):p.5415-21. 20.Tamashiro,K.L.,M.M.Nguyen,and R.R.Sakai,Social stress:from rodents to primates.Front Neuroendocrinol,2005.26(1):p.27-40. 21.Can,A.,et al.,The tail suspension test.J Vis Exp,2012(59):p.e3769. 22.Duncko,R.,et al.,Altered function of peripheral organ systems in rats exposed to chronic mild stress model of depression.Cell Mol Neurobiol,2001.21(4):p.403-11. 23.Ngondo,S,et al.,Christensenella timonensis,a new bacterial species isolated from the human gut.New Microbe and New Infect 2016;13:32-33. 24.Ngondo,S,et al.,Christensenella massiliensis,a new bacterial species isolated from the human gut.New Microbe and New Infect 2016;12:69-70. 25.Meir Kolthof JP,et al.,Genome seguence-based species delimitation with confidence intervals and improved distance functions,BMC Bioinformatics volume 14,Article number:60(2013). 26.Meir Kolthof JP,et al.,Complete genome sequence of DSM30083 T ,the typestrain(U5 / 41 T)of Escherichia coli,and a proposal for delineating subspecies in microbial taxonomy,Standards in Genomic Sciences volume 9,Article number:2(2014). 27.Morotomy M,et al.,Description of Christensenella minuta gen.nov.,sp.nov.,isolated from human faeces,which forms a distinct branch in the order Clostridiales,and proposal of Christensenellaceae fam.nov.,International Journal of Systematic and Evolutionary Microbiology(2012),62,144-149.
Claims
1. A strain of Christensenella minuta having the accession number DSM32891.
2. A strain derived from the strain according to claim 1.
3. The strain according to claim 1 or 2, wherein the strain is a genetically modified mutant.
4. The strain according to any one of claims 1 to 3, wherein the strain is in the form of viable or non-viable cells.
5. A cellular component, a metabolic product, a secreted molecule, or any combination thereof, obtained from the strain according to any one of claims 1 to 4.
6. A composition comprising the strain of Christensenella minuta according to any one of claims 1 to 4, or a cellular component, a metabolite, a secreted molecule, or any combination thereof according to claim 5.
7. The composition of claim 6 , wherein the composition also comprises at least one bioactive ingredient.
8. The composition according to any one of claims 6 or 7, wherein the composition also comprises at least one microorganism which is of a different strain than the bacterium according to any one of claims 1 to 4.
9. The composition according to claim 8 , wherein the microorganism is an enterobacteria or a lactic acid bacterium.
10. The composition according to any one of claims 6 to 9, wherein the composition is a pharmaceutical composition.
11. The composition of claim 10, wherein the composition also comprises at least one pharma- ceutically acceptable vehicle and / or excipient.
12. 12. The composition of claim 10 or claim 11, wherein the composition is presented in a form suitable for oral, sublingual, nasal, bronchial, lymphatic, rectal, transdermal, inhalation, or parenteral administration.
13. The composition according to any one of claims 6 to 9, wherein the composition is a nutritional composition.
14. 14. The composition of claim 13, wherein the nutritional composition is a foodstuff, a supplement, a nutraceutical, a probiotic, or a synbiotic.
15. The composition according to claim 14, wherein the foodstuff is selected from the list consisting of a dairy product, a vegetable product, a meat product, an aperitif, a chocolate, a beverage, or a baby food.
16. The composition comprises 10 4 ~10 14 16. The composition according to any one of claims 6 to 15, having a concentration of said bacteria of colony forming units (CFU).
17. A strain of Christensenella minuta according to any one of claims 1 to 4, a cellular component, a metabolite, a secreted molecule or any combination thereof according to claim 5, or a composition according to any one of claims 6 to 16, for use as a medicament or as a pharmaceutical.
18. 2. A Christensenellaceae bacterium, or a composition comprising said Christensenellaceae bacterium, for use in the prevention and / or treatment of mood disorders and / or stress disorders and / or anxiety disorders and / or migraines.
19. 2. A Christensenellaceae bacterium, or a composition comprising said Christensenellaceae bacterium, for use as an adjuvant in the treatment of mood disorders and / or stress disorders and / or anxiety disorders and / or migraines.
20. 20. The Christensenellaceae bacterium or a composition comprising a Christensenellaceae bacterium for use according to claim 18 or 19, wherein the mood disorder is selected from the list comprising depression, major depression, atypical depression, typical or melancholic depression, psychogenic depression, catatonic depression, perinatal depression, bipolar disorder, seasonal affective disorder, dysthymia, depressive personality disorder, dual depression, unspecified depressive disorder, recurrent brief depressive disorder, minor depression, altered mental status, and mood disorder induced by substance abuse or by the use of a drug such as a drug of abuse.
21. 20. The Christensenellaceae bacterium for use according to claim 18 or 19, wherein the stress disorder is selected from reactive attachment disorder, disinhibited social engagement disorder, post-traumatic stress disorder (PTSD), acute stress disorder, and adjustment disorder.
22. 20. The Christensenellaceae bacterium for use according to claim 18 or 19, wherein the anxiety disorder is selected from panic attacks, panic disorder, agoraphobia, social phobia or social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder (ASD), generalized anxiety disorder, or acute stress disorder.
23. 23. The Christensenellaceae bacterium, or a composition comprising Christensenellaceae bacteria, for use according to any one of claims 18 to 22, wherein the Christensenellaceae bacterium is a bacterium of the genus Christensenella.
24. 24. The Christensenella bacterium or a composition comprising Christensenella bacterium for use according to claim 23, wherein the Christensenella bacterium is selected from the species Christensenella minuta, Christensenella timonensis, Christensenella massiliensis, or any combination thereof.
25. 25. The Christensenella bacterium or a composition comprising Christensenella bacterium for use according to claim 24, wherein the Christensenella bacterium is either the Christensenella massiliensis strain having the accession number DSM 102344 or the Christensenella timonensis strain having the accession number DSM 102800 or a combination thereof.
26. 25. The Christensenella bacterium or a composition comprising Christensenella bacterium for use according to claim 24, wherein the Christensenella bacterium is selected from the bacteria according to any one of claims 1 to 4, a strain of Christensenella minuta having the accession number DSM 32891, a strain of Christensenella minuta having the accession number DSM 22607, or a combination thereof.
27. 27. The Christensenellaceae bacterium or a composition comprising Christensenellaceae bacteria for use according to any one of claims 18 to 26, wherein the Christensenellaceae bacteria is in the form of viable and / or non-viable cells.
28. 28. The Christensenellaceae bacterium for use according to any one of claims 18 to 27, or a composition comprising said Christensenellaceae bacterium, wherein said Christensenellaceae bacterium comprises a 16S rRNA sequence having at least 90% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 99.5% identity to the 16S rRNA sequence of a strain of Christensenella minuta having the deposit number DSM 32891 (SEQ ID NO: 3), or wherein said Christensenellaceae bacterium comprises a strain of Christensenella minuta having the deposit number DSM 32891.
29. The bacterium for use according to any one of claims 17 to 28, which is for use in a subject selected from a human or a non-human animal.
30. 30. The bacterium for use according to claim 29, wherein the non-human animal is selected from pets, livestock animals, zoo animals, mammals, dogs, cats, guinea pigs, ferrets, hamsters, pigs, cows, goats, sheep, horses, mice and rats.
31. The use comprises: 4 ~10 14 The bacterium for use according to any one of claims 17 to 30, comprising administration of colony forming units (CFU) of
32. Use of a bacterial strain according to any one of claims 1 to 4, a cellular component, a metabolite, a secreted molecule, or a combination thereof according to claim 5, or a composition according to any one of claims 6 to 16 for the preparation of a food product.
